FBIO close: $6.77 on 2023-08-21 to $2.87 on 2026-08-21.
Split-adj closes · 240 of 1,603 · price returnⓘ
At a glance
Short interest7.0% of sh out
Days to cover12.0d
13F net flow (QoQ)−0.66%
Top-10 13F concentration72.5%
Next report (est.)2026-11-12
SI 2026-07-31 · 13F 2026-Q1ⓘ
Key fundamentalsFY 2025
Sales (TTM)$68.5M
Earnings (TTM)$111.8M
ROE18.8%
Net margin10.8%
ROIC−323.7%
Debt / equity1.05×
Sales growth 3Y−5.8%
FY ratios · TTM sales/earnings (USD)ⓘ
Trailing returns
YTD−21.6%
1Y+28.1%
3Y−57.6%
5Y−94.0%
Since incept. (ann.)−29.8%
Total return · from 2020-04-01ⓘ
Risk
Ann. volatility (1Y)82.8%
Ann. volatility (3Y)92.0%
Sharpe (1Y)0.83
Sharpe (3Y)0.14
Max drawdown (1Y)−49.3%
Max drawdown (3Y)−80.7%
Beta (3Y vs SPY)1.38
Daily returns, ann.ⓘ
Top institutional holders13F 2026-Q1
Manager
Shares
Value
% sh out
QoQ
Opaleye Management Inc.
1.0M
$3M
—
−4.4%
VANGUARD CAPITAL MANAGEMENT LLC
966,030
$3M
—
new
SHIKIAR ASSET MANAGEMENT INC
305,469
$852,000
—
+9.7%
GEODE CAPITAL MANAGEMENT, LLC
290,255
$810,110
—
+10.6%
GSA CAPITAL PARTNERS LLP
254,134
$709,000
—
+604.5%
NORTHERN TRUST CORP
230,053
$641,848
—
−4.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
210,745
$587,979
—
−8.3%
BlackRock, Inc.
197,085
$549,867
—
−1.7%
Δ vs 2025-Q4 · % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.ⓘ
Latest reported quarterslast report 2026-08-13
Period end
Reported
EPS
EPS YoY
Revenue
Rev YoY
2026-06-30
2026-08-13
−$0.08
−117.8%
$18.7M
+14.0%
2026-03-31
2026-05-14
$2.82
—
$16.0M
+22.1%
2025-12-31
2026-03-31
—
—
$16.1M
+6.3%
2025-09-30
2025-11-14
$0.11
—
$17.6M
+20.5%
As-reported XBRL · next 2026-11-12 est.ⓘ
Segment mixFY2025 (ended Dec 2025)
Journey 98% · Avenue Therapeutics Inc 2%
business · TAGGED revenueⓘ
Basis & disclosures
EOD closes · nothing imputed or averaged · absent “—”
As-of differs by block · 13F = US long, 45+d lag, LOWER bound
Not investment advice · no recommendation, price target or solicitation
EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
